Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05ZXZ
|
|||
| Former ID |
DNC000277
|
|||
| Drug Name |
BAY 57-1293
|
|||
| Synonyms |
Pritelivir; 348086-71-5; BAY-57-1293; UNII-07HQ1TJ4JE; AIC316; BAY57-1293; 07HQ1TJ4JE; Pritelivir (BAY 57-1293); N-Methyl-N-(4-methyl-5-sulfamoylthiazol-2-yl)-2-(4-(pyridin-2-yl)phenyl)acetamide; N-methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-(4-pyridin-2-ylphenyl)acetamide; Pritelivir [INN]; AIC-316; AIC 316; AC1LANY1; PritelivirBAY-57-1293; SCHEMBL1074614; Pritelivir(BAY 57-1293); DTXSID70188344; EX-A247; MolPort-029-887-140; IVZKZONQVYTCKC-UHFFFAOYSA-N; HMS3653B15; BCP08742
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Herpes simplex virus infection [ICD-11: 1F00; ICD-10: B00; ICD-9: 54] | Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H18N4O3S2
|
|||
| Canonical SMILES |
CC1=C(SC(=N1)N(C)C(=O)CC2=CC=C(C=C2)C3=CC=CC=N3)S(=O)(=O)N
|
|||
| InChI |
1S/C18H18N4O3S2/c1-12-17(27(19,24)25)26-18(21-12)22(2)16(23)11-13-6-8-14(9-7-13)15-5-3-4-10-20-15/h3-10H,11H2,1-2H3,(H2,19,24,25)
|
|||
| InChIKey |
IVZKZONQVYTCKC-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 348086-71-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Herpes simplex virus Helicase-primase (HSV UL8) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01658826) Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes. U.S. National Institutes of Health. | |||
| REF 2 | Helicase primase: targeting the Achilles heel of herpes simplex viruses. Antivir Chem Chemother. 2004 May;15(3):135-40. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.